Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa
- PMID: 19248549
- PMCID: PMC2922752
- DOI: 10.1159/000325079
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa
Abstract
Objective: To evaluate the epidemiology of the human papillomavirus (HPV) type and correlate it with the Papanicolaou smears in human immunodeficiency virus-seropositive women in Johannesburg, South Africa.
Study design: In a cohort of 148 women, HPV DNA testing was performed with the Roche HPV genotyping test (Branchburg, New Jersey, U.S.A). Papanicolaou smears were performed by standard cytology utilizing 2001 Bethesda reporting guidelines.
Results: The average age and CD4 count of the participants was 35 years and 255 cells per mm3, respectively. Fifty-four percent had abnormal Papanicolaou smears; 66% of the abnormal cytology was low grade changes, with 33% assessed as having high grade changes. HPV DNA was found in 95% of the 148 subjects assessed, with 83% having 1 or more HPV oncogenic types. Common oncogenic types were 16, 35, 53 and 18. When HPV results were stratified by CD4, there was a significant risk of an oncogenic HPV type in women with CD4 <200. Significant odds ratios for high grade lesions were seen in HPV types 16, 35, 51, 66, 69 and 73.
Conclusion: The results of HPV typing illustrate the diverse range of oncogenic HPV and high prevalence of oncogenic type. These results highlight the need for improved access to Papanicolaou smear screening for this population.
Similar articles
-
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.JAMA. 2005 Mar 23;293(12):1471-6. doi: 10.1001/jama.293.12.1471. JAMA. 2005. PMID: 15784870
-
HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.JAMA. 2000 Jan 5;283(1):81-6. doi: 10.1001/jama.283.1.81. JAMA. 2000. PMID: 10632284
-
Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study.J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42. doi: 10.1097/00126334-200108150-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11511819
-
The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women.AIDS. 2001 Nov 9;15(16):2157-64. doi: 10.1097/00002030-200111090-00011. AIDS. 2001. PMID: 11684935 Clinical Trial.
-
Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of anti-retroviral therapy.AIDS. 2017 Jan 14;31(2):273-285. doi: 10.1097/QAD.0000000000001301. AIDS. 2017. PMID: 27755107
Cited by
-
Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa.J Int AIDS Soc. 2012 Jun 7;15(2):17382. doi: 10.7448/IAS.15.2.17382. J Int AIDS Soc. 2012. PMID: 22713259 Free PMC article.
-
Human papillomavirus vaccines: where do they fit in HIV-infected individuals?Curr HIV/AIDS Rep. 2012 Sep;9(3):278-86. doi: 10.1007/s11904-012-0128-6. Curr HIV/AIDS Rep. 2012. PMID: 22744002 Review.
-
Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa.Int J Cancer. 2017 Aug 1;141(3):488-496. doi: 10.1002/ijc.30749. Epub 2017 May 19. Int J Cancer. 2017. PMID: 28440019 Free PMC article.
-
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa.Cancer Causes Control. 2010 Mar;21(3):433-43. doi: 10.1007/s10552-009-9475-z. Epub 2009 Dec 1. Cancer Causes Control. 2010. PMID: 19949850 Free PMC article.
-
Identification of human papillomaviruses from formalin-fixed, paraffin-embedded pre-cancer and invasive cervical cancer specimens in Zambia: a cross-sectional study.Virol J. 2015 Jan 16;12:2. doi: 10.1186/s12985-014-0234-8. Virol J. 2015. PMID: 25591541 Free PMC article.
References
-
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525–541. - PubMed
-
- Shew ML, Fortenberry D, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160:151–156. - PubMed
-
- Bower M, Mazhar D, Stebbing J. Should cervical cancer be an acquired immunodeficiency syndrome–defining cancer? J Clin Oncol. 2006;24:2417–2419. - PubMed
-
- Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials